HIGHLIGHTS
- who: Noppaket Singkham et al. from the Division of Clinical Pharmacy, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand have published the research: Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation, in the Journal: Pharmaceutics 2022, 14, 1744. of /2022/
- what: This study developed a population PK model of rivaroxaban in Thai DOAC-eligible AF patients. In this investigation, rivaroxaban concentrations were determined indirectly using commercially available Anti-Xa assays (BIOPHENTM Heparin LRT) with validated specific rivaroxaban calibrators. 11 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.